RIP Jim McLaughlin, 1948-2015
irishphiladelphia.com – Posted By Denise Foley
July 30, 2015
Though many recalled Jim McLaughlin’s “unbounded friendliness”—as Father Feeney put it—the truth is that the greatest of his “eulogy virtues” echoed the Jesuit principle that guides his beloved St. Joe’s: “In all things to love and to serve.”
Read more at irishphiladelphia.com
IABCN member, Kate Brennan Ward, will serve on the Executive Leadership Team of the 2016 “Salute to Chester County Women of Achievement” in support of the March of Dimes mission to give all babies a fighting chance.
This fantastic event (which usually sells out) will take place on Wednesday, October 19 at Aronimink Golf Club and will be a very special evening celebrating our three outstanding honorees. To learn more, please click HERE.
The Irish American Business Chamber & Network is thrilled to join the Irish Immigration Center and Consul General of Ireland Barbara Jones in welcoming newly elected Tánaiste Frances Fitzgerald TD, Minister for Justice and Equality, to Philadelphia.
Today’s Graphics Introduces MarCore™ … Your all-in-one, eCommerce solution for better brand and asset management.
MarCore on-line portals are amazing. TGI has helped numerous marketing, sales, and human resource teams of all sizes become more efficient, save time, and reduce costs. The system utilizes familiar shopping cart functionality, making it extremely easy to use. Improves efficiency by automating ordering on all sorts of corporate, sales, and marketing collateral/material.
The system delivers unbelievable value for virtually any size company…reduces marketing, administrative, and inventory costs, provides real time reporting, maintains brand consistency, and is available to you 24/7.
 Almac Group’s Rapid Launch Services Support U.S. Approval of Intercept Pharmaceutical’s First Commercial Orphan Drug Product |
|
Craigavon, 14 July 2016 – Almac Group, the global contract development and manufacturing organisation, wishes to congratulate its long-term client partner Intercept Pharmaceuticals, Inc. on the U.S. Food and Drug Administration (FDA) approval of their first orphan drug product obeticholic acid, marketed in the US as Ocaliva®. Ocaliva has been granted accelerated approval for the treatment of primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.The partnership between Intercept and Almac commenced in 2013, with Almac’s Pharmaceutical Development teams supporting the early phase development of various dosage forms of Ocaliva. Building on this partnership, Almac’s commercial teams have worked with Intercept for the commercial packaging including packaging design & artwork of the now FDA approved drug product Ocaliva. Read More |
